On September 11, 2023, Dianthus Therapeutics, Inc. closed the transaction. The company has received $71.987749 million private investment for the issuance of 2,873,988 common stock at a purchase price $23.34 per share for a gross proceeds $67.07888 million and 210,320 pre-funded warrants at a purchase price $23.34 per warrant for a gross proceeds of $4.908869 million in the transaction.